7th Annual Immuno-Oncology Summit 2019
Date: August 5 - 9, 2019
Venue: Westin Boston Waterfront, Boston, MA USA
Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean

Update History
2019/07/23
Speaker,Sponsor updated
2019/07/09
Sponsor updated
2019/06/20
Sponsor updated
2019/05/17
Agenda,Sponsor updated
2019/04/10
Agenda updated
2019/04/09
Agenda,Sponsor updated
2019/03/28
Sponsor updated
Download
Brochure (PDF)
Download Brochure(PDF)

Industry’s Leading Immuno-Oncology Annual Meeting

Join over 675 IO thought leaders at industry's leading Immuno-Oncology event and learn about the latest research in a comprehensive 12-track program, network with decision makers and build lasting collaborations with an international mix of delegates, and gain actionable solutions to drive your organization's next-generation immunotherapy programs.

Featured Speakers

Litao Zhang, Vice President, Leads Discovery and Optimization, Bristol-Myers Squibb

Adya_Neeraj

Neeraj Adya, PhD, Director, Pharmacodiagnostics, Bristol-Myers Squibb

John Desjarlais, PhD, Senior Vice President, Research, CSO, Xencor

Pamela Carroll, PhD, Senior Vice President, Immuno-Oncology, Genocea

Jianda Yuan, MD, PhD, Senior Director, Translational Oncology, Merck

Andrew Allen, President and CEO, Gritstone Oncology

Michael Woo, Head, Immuno-Oncology, Business Development, Novartis

Catherine Sabatos-Peyton, Director, Exploratory Immuno-Oncology, Novartis

Cokey Nguyen, Senior Director, Oncology R&D, Pfizer

Jon Wigginton, Senior Vice President & CMO, MacroGenics

Adrian Bot, Vice President, Translational Sciences, Kite, a Gilead Company

Tara Arvedson, PhD, Director, Oncology Research, Amgen

Philip Arlen, President & CEO, Precision Biologics

Arthur Krieg, Founder & CSO, Checkmate Pharmaceuticals

Kevin R. Webster, Senior Vice President, eFFECTOR Therapeutics

Stephen Doberstein, Chief Research and Development Officer, Nektar Therapeutics

David Kirn, Co-Founder & Executive Chairman, IGNITE Immunotherapy

Kathryn McCabe, Senior Director, Emerging Technology and Innovation, Eli Lilly

Scott M. DeWire, Global Head, Business Development and Licensing, Boehringer Ingelheim

Griffith_Melinda

Melinda Griffith, JD, Vice President, Strategic Alliances; Chief Legal Counsel, Parker Institute for Cancer Immunotherapy

Caron Jacobson, MD, Medical Director, Immune Effector Cell Therapy Program, Dana Farber Cancer Institute

Howard Kaufman, PhD, CMO, Replimune

Paola Grandi, PhD, CSO, Cold Genesys

Preet M. Chaudhary, MD, PhD, Chief of Hematology, University of Southern California Keck School of Medicine

John Quackenbush, PhD, Chair, Department of Biostatistics, Harvard T.H. Chan School of Public Health


Why attend CHI’s Immuno-Oncology Summit?


NETWORK
with 675+ IO thought leaders from 28 countries and 400 companies

LEARN
the latest developments in immuno-oncology from 175+ scientific presentations and 40+ posters

CUSTOMIZE
your comprehensive 5-day program by selecting from 12-tracks, 2 training seminars, 1 partnering forum and 1 course

CONNECT
at the industry’s leading Immuno-Oncology meeting, with 72% of delegates from biotech and pharma

COLLABORATE
and build lasting business relationships with IO decision-makers: 46% of delegates are executive/director level

INNOVATE
your projects with technology solutions from 40+ exhibitors and 20+ technical presentations

BRAINSTORM
actionable solutions at the expertly-facilitated roundtable discussions

FOCUS
on your agenda by track hopping between concurrent tracks

SHOWCASE
your research by presenting a scientific poster


Why attend CHI’s Immuno-Oncology Summit?


NETWORK
with 675+ IO thought leaders from 28 countries and 400 companies

LEARN
the latest developments in immuno-oncology from 175+ scientific presentations and 40+ posters

CUSTOMIZE
your comprehensive 5-day program by selecting from 12-tracks, 2 training seminars, partnering forum and 4 courses

CONNECT
at the industry’s leading Immuno-Oncology meeting, with 72% of delegates from biotech and pharma

COLLABORATE
and build lasting business relationships with IO decision-makers: 46% of delegates are executive/director level

INNOVATE
your projects with technology solutions from 40+ exhibitors and 20+ technical presentations

BRAINSTORM
actionable solutions at the expertly-facilitated roundtable discussions

FOCUS
on your agenda by track hopping between concurrent tracks

SHOWCASE
your research by presenting a scientific poster

Emerging Company Showcase

The Immuno-Oncology Investing and Partnering Forum will play host to an Emerging Company Showcase as part of the program agenda. This showcase allows immuno-oncology companies to pitch their drug, device, diagnostic, or software to an audience of investors, CEOs, and executives in the field.